Literature DB >> 10343886

Future scenarios for the prevention and delay of Alzheimer disease onset in high-risk groups. An ethical perspective.

S G Post1.   

Abstract

CONTEXT: Alzheimer disease (AD) presents a major scientific and social challenge in our aging society. Strategies to prevent or delay onset of symptoms, as well as to prevent the decline into the advanced stage, are urgently needed. While these strategies do not yet exist in a proven and clinically applicable form, the science is progressing rapidly.
OBJECTIVES: The pre-eminent goal is to identify asymptomatic persons at high risk for AD and to then apply pharmacologic and lifestyle interventions that delay onset of disease. In this scenario, genetic susceptibility testing may eventually prove accurate enough to be of use in identifying at-risk individuals decades before probable onset, allowing maximal preventive efforts. Second, an important goal is to delay or prevent the onset of moderate and advanced AD through applying compounds that slow the progression of disease, thereby allowing patients to die of unrelated ailments of old age before they lose their capacities to recognize loved ones and to communicate by speech.
CONCLUSIONS: This article provides a discussion of these strategies with attention to a variety of ethical issues that should be of concern to physicians and caregivers. An assessment of the scientific evidence for preventing or delaying AD should be coupled with values analysis.

Entities:  

Keywords:  Genetics and Reproduction; Mental Health Therapies; Professional Patient Relationship

Mesh:

Substances:

Year:  1999        PMID: 10343886     DOI: 10.1016/s0749-3797(98)00139-1

Source DB:  PubMed          Journal:  Am J Prev Med        ISSN: 0749-3797            Impact factor:   5.043


  3 in total

1.  Issues of clinical trial design and data interpretations in hypertension.

Authors:  L H Kuller
Journal:  Curr Hypertens Rep       Date:  1999-08       Impact factor: 5.369

Review 2.  [Effective, indicated--and yet without benefit? The goals of dementia drug treatment and the well-being of the patient].

Authors:  Matthis Synofzik
Journal:  Z Gerontol Geriatr       Date:  2006-08       Impact factor: 1.281

Review 3.  Apolipoprotein E in Cardiometabolic and Neurological Health and Diseases.

Authors:  Jeyashree Alagarsamy; Anja Jaeschke; David Y Hui
Journal:  Int J Mol Sci       Date:  2022-08-31       Impact factor: 6.208

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.